Sanara MedTech acquires exclusive U.S. rights to OsStic fracture product; invests up to €8M for 12.5% of BMI

Sanara MedTech Inc.

Exclusive U.S. license/distribution for OsStic and ARC delivery tech; initial five-year term with renewal options.
Sanara invests up to €8M (€4M initial incl. debt conversion) for ~12.5% equity in BMI; remaining €4M tied to milestones.
OsStic received FDA Breakthrough Device Designation Dec 2023; U.S. market launch expected Q1 2027.
Targets >100,000 annual periarticular fracture procedures; complements existing surgical portfolio.
Company's Chief Corporate Development Officer Tyler Palmer appointed to BMI board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.